While the American Society of Clinical Oncology (ASCO) annual meeting, to be held June 1-5 in Chicago, has a long lineup of immune-oncology hits and misses, there’s plenty to stay on top of outside of immunotherapy, as shown by the ASCO preview report from Pharma Intelligence’s Pharma Biomedtracker and Datamonitor Healthcare analysts.
[Sidebar#SC123108]







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)